Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults

NCT04952766 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

196

Enrollment

OTHER

Sponsor class

Conditions

Kidney Transplant
Myeloma
Cancer
Hematologic Malignancy
Multiple Sclerosis
Hypergammaglobulinemia
Malignant Tumor
Hiv
Diabetes Type 2

Interventions

BIOLOGICAL: Biological samples

Sponsor

Centre Hospitalier Régional d'Orléans